Literature DB >> 25545203

Contrast-enhanced MRI in preoperative assessment of myometrial and cervical invasion, and lymph node metastasis: diagnostic value and error analysis in endometrial carcinoma.

Fei Teng1, Yan-Fang Zhang, Ying-Mei Wang, Jing Yu, Xu Lang, Wen-Yan Tian, Chang-Xin Jiang, Feng-Xia Xue.   

Abstract

OBJECTIVE: To determine the ability of contrast-enhanced magnetic resonance imaging to predict myometrial invasion, cervical invasion, and pelvic lymph node metastasis in endometrial carcinoma and to analyze factors that lead to errors in this identification.
DESIGN: A retrospective study.
SETTING: University general hospital. POPULATION: A total of 167 women diagnosed with endometrial carcinoma.
METHODS: All patients received a preoperative contrast-enhanced magnetic resonance imaging scan. Histopathological findings were used as the definitive diagnosis. MAIN OUTCOME MEASURES: The results were compared with histopathological findings, factors that make accurate assessment of myometrial invasion, cervical invasion, and pelvic lymph node metastasis difficult by contrast-enhanced magnetic resonance imaging were analyzed.
RESULTS: The sensitivity, specificity, diagnostic accuracy, positive predictive values, and negative predictive values of contrast-enhanced magnetic resonance imaging were 90.9, 91.8, 91.6, 73.2 and 97.6%, respectively, for identifying deep myometrial invasion; 84.2, 96.0, 94.6, 72.7 and 97.9%, respectively, for identifying cervical invasion; and 45.0, 91.2, 85.6, 40.9 and 92.4%, respectively, for identifying pelvic lymph node metastasis. The main causes of error in contrast-enhanced magnetic resonance imaging were myomas, cornual lesions, deep myometrial invasion, large tumor size, non-endometrioid tumor type, and lower tumor grade.
CONCLUSION: Contrast-enhanced magnetic resonance imaging has a high accuracy and a low tendency to produce false-negative predictive values. Gynecological oncologists should combine the imaging data and clinical information to make therapeutic decisions and avoid diagnostic errors.
© 2014 Nordic Federation of Societies of Obstetrics and Gynecology.

Entities:  

Keywords:  Cervical invasion; endometrial carcinoma; error analysis; magnetic resonance imaging; myometrial invasion; pelvic lymph node metastasis

Mesh:

Substances:

Year:  2015        PMID: 25545203     DOI: 10.1111/aogs.12570

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  16 in total

1.  Endometrial cancer with cervical stromal invasion: diagnostic accuracy of diffusion-weighted and dynamic contrast enhanced MR imaging at 3T.

Authors:  Gigin Lin; Yu-Ting Huang; Angel Chao; Yu-Chun Lin; Lan-Yan Yang; Ren-Chin Wu; Hsin-Ying Lu; Shu-Hang Ng; Koon-Kwan Ng; Chyong-Huey Lai
Journal:  Eur Radiol       Date:  2016-09-09       Impact factor: 5.315

2.  Diagnostic Accuracy of Clinical Biomarkers for Preoperative Prediction of Lymph Node Metastasis in Endometrial Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Casper Reijnen; Joanna IntHout; Leon F A G Massuger; Fleur Strobbe; Heidi V N Küsters-Vandevelde; Ingfrid S Haldorsen; Marc P L M Snijders; Johanna M A Pijnenborg
Journal:  Oncologist       Date:  2019-06-11

3.  ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

Authors:  Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2021-02       Impact factor: 4.064

Review 4.  Endometrial cancer with congenital uterine anomalies: 3 case reports and a literature review.

Authors:  Jinping Gao; Jintian Zhang; Wenyan Tian; Fei Teng; Huiying Zhang; Xuhong Zhang; Yingmei Wang; Fengxia Xue
Journal:  Cancer Biol Ther       Date:  2017-01-24       Impact factor: 4.742

5.  Preoperative Prediction Value of Pelvic Lymph Node Metastasis of Endometrial Cancer: Combining of ADC Value and Radiomics Features of the Primary Lesion and Clinical Parameters.

Authors:  Juan Bo; Haodong Jia; Yu Zhang; Baoyue Fu; Xueyan Jiang; Yulan Chen; Bin Shi; Xin Fang; Jiangning Dong
Journal:  J Oncol       Date:  2022-06-30       Impact factor: 4.501

6.  Preoperative prediction of deep myometrial invasion and tumor grade for stage I endometrioid adenocarcinoma: a simple method of measurement on DWI.

Authors:  Bin Yan; Xiufen Liang; Tingting Zhao; Chen Niu; Caixia Ding; Wenjun Liu
Journal:  Eur Radiol       Date:  2018-07-23       Impact factor: 5.315

7.  Perioperative and long-term outcomes of laparoscopy and laparotomy for endometrial carcinoma.

Authors:  Xianghua Yin; Min Shi; Jianbo Xu; Qinhao Guo; Huan Wu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 8.  Endometrial Cancer MRI staging: Updated Guidelines of the European Society of Urogenital Radiology.

Authors:  Stephanie Nougaret; Mariana Horta; Evis Sala; Yulia Lakhman; Isabelle Thomassin-Naggara; Aki Kido; Gabriele Masselli; Nishat Bharwani; Elizabeth Sadowski; Andrea Ertmer; Milagros Otero-Garcia; Rahel A Kubik-Huch; Teresa M Cunha; Andrea Rockall; Rosemarie Forstner
Journal:  Eur Radiol       Date:  2018-07-11       Impact factor: 5.315

Review 9.  Different imaging techniques for the detection of pelvic lymph nodes metastasis from gynecological malignancies: a systematic review and meta-analysis.

Authors:  Yi Gong; Qingming Wang; Li Dong; Yiping Jia; Chengge Hua; Fanglin Mi; Chunjie Li
Journal:  Oncotarget       Date:  2017-02-21

10.  Autocrine motility factor promotes endometrial cancer progression by targeting GPER-1.

Authors:  Yiran Li; Yuanhui Jia; Yiding Bian; Huan Tong; Junjie Qu; Kai Wang; Xiao-Ping Wan
Journal:  Cell Commun Signal       Date:  2019-03-05       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.